Document is current

Any future updates will be listed below

Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC)

Crossref DOI link: https://doi.org/10.1007/s43441-020-00194-4

Published Online: 2020-08-06

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark